Treatment Decisions for Patients Diagnosed with Intermediate Risk Acute Myeloid Leukemia/AML

Physicians treating hematologic malignancies increasingly order targeted sequencing panels to interrogate recurrently mutated genes, the impact of which on clinical decision making is not well understood. This study provided insights into how physicians are currently using multigene panels capable of detecting relatively rare AML cells.

Barnell, E.K., Newcomer, K.F., Skidmore, Z.L., Krysiak, K., Anderson, S.R., Wartman, L.D., Oh, S.T., Welch, J.S., Stockerl-Goldstien, K.E., Vij, R., Cashen, A.F., Pusic, I., Westervelt, P., Abboud, C.N., Ghobadi, A., Uy, G.L., Schroeder, M.A., Dipersio, J.F., Politi, M.C., Spencer, D.H., Duncavage, E.J., Ley, T.J., Griffith, M., Jacoby, M.A., Griffith, O.L. (2021) Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia. JCO Precis Oncol. 5:PO.20.00182.